AMNOG

AMNOG (pronunciation: /ˈæmnɒg/) is an acronym for the German term Arzneimittelmarktneuordnungsgesetz, which translates to Pharmaceutical Market Reorganization Act in English. This legislation was enacted in Germany in 2011 to regulate the pricing of new pharmaceutical products.

Etymology

The term AMNOG is derived from the German language. Arzneimittel translates to pharmaceuticals, Markt to market, neuordnung to reorganization, and gesetz to law or act.

Overview

The AMNOG process is a health policy instrument that aims to limit the costs of pharmaceuticals in Germany. It requires pharmaceutical companies to provide evidence of the additional benefit of new drugs over existing treatments. The level of additional benefit then forms the basis for price negotiations between the statutory health insurance (GKV-SV) and the pharmaceutical companies.

Related Terms

• Pharmaceutical Pricing
• Health Policy
• Statutory Health Insurance (GKV-SV)
• Pharmaceutical Companies

See Also

• Pharmaceutical Industry in Germany
• Healthcare in Germany

External links

• Medical encyclopedia article on AMNOG
• Wikipedia's article - AMNOG

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski